<div id="readability-page-1"><p>LB Pharmaceuticals Inc (NASDAQ:LBRX - Get Free Report) reached a new 52-week high during trading on Tuesday . The company traded as high as $32.49 and last traded at $31.67, with a volume of 208549 shares trading hands. The stock had previously closed at $30.52.</p><div><p><span></span><span>Get <strong>LB Pharmaceuticals</strong> alerts:</span></p></div><h2>Analysts Set New Price Targets</h2><p>A number of research analysts have recently issued reports on the stock. Stifel Nicolaus raised their price target on shares of LB Pharmaceuticals from $35.00 to $40.00 and gave the stock a &#34;buy&#34; rating in a research report on Friday, March 27th. Craig Hallum assumed coverage on shares of LB Pharmaceuticals in a research report on Friday, April 10th. They issued a &#34;buy&#34; rating and a $36.00 price target on the stock. Roth Mkm assumed coverage on shares of LB Pharmaceuticals in a research report on Friday, January 9th. They issued a &#34;buy&#34; rating and a $31.00 price target on the stock. Finally, Weiss Ratings  restated a &#34;sell (e)&#34; rating on shares of LB Pharmaceuticals in a research report on Monday, December 29th. One research analyst  has rated the stock with a Strong Buy rating, four have issued  a Buy rating, one  has assigned  a Hold rating and one  has issued  a Sell rating to the stock. Based on data from MarketBeat, LB Pharmaceuticals  has a consensus rating of &#34;Moderate Buy&#34; and an average target price of $35.25.</p><p><b>Get Our Latest Analysis on LBRX</b></p><h2>LB Pharmaceuticals Trading Up 3.8%</h2><p>The stock's 50-day moving average price is $24.94 and its 200-day moving average price is $20.95. The company has a market capitalization of $907.98 million and a P/E ratio of -29.88. </p><p>LB Pharmaceuticals (NASDAQ:LBRX - Get Free Report) last posted its quarterly earnings results on Thursday, March 26th. The company reported ($0.45) earnings per share (EPS) for the quarter, hitting analysts' consensus estimates of ($0.45).  Sell-side analysts expect that  LB Pharmaceuticals Inc will post -3.85 earnings per share for the current fiscal year. </p><h2>Institutional Trading of LB Pharmaceuticals</h2><p>A number of large investors have recently modified their holdings of LBRX. California State Teachers Retirement System acquired a new stake in shares of  LB Pharmaceuticals in the 4th quarter worth about $26,000.  Bank of America Corp DE acquired a new stake in shares of  LB Pharmaceuticals in the 3rd quarter worth about $27,000.  Russell Investments Group Ltd. acquired a new stake in shares of  LB Pharmaceuticals in the 4th quarter worth about $34,000.  Strs Ohio acquired a new stake in shares of  LB Pharmaceuticals in the 4th quarter worth about $76,000.  Finally, Persistent Asset Partners Ltd acquired a new stake in shares of  LB Pharmaceuticals in the 4th quarter worth about $91,000. </p><h2>LB Pharmaceuticals Company Profile</h2> (Get Free Report)<p>We are a clinical-stage biopharmaceutical company developing novel therapies for the treatment of schizophrenia, bipolar depression, and other neuropsychiatric diseases. We are building a pipeline that leverages the broad therapeutic potential of our lead product candidate, LB-102, which we believe has the potential to be the first benzamide antipsychotic drug approved for neuropsychiatric disorders in the United States. LB-102 is a new chemical entity and a methylated derivative of amisulpride, a second-generation antipsychotic drug approved in over 50 countries, not including the United States, because the development and regulatory requirements of the U.S.</p><h2>Featured Articles</h2><ul><li>Five stocks we like better than LB Pharmaceuticals</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in LB Pharmaceuticals Right Now?</h2><p>Before you consider LB Pharmaceuticals, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and LB Pharmaceuticals wasn't on the list.</p><p>While LB Pharmaceuticals currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

LBRX

<p>LB Pharmaceuticals (NASDAQ:LBRX) reached a new 52-week high of $32.49 during trading, closing at $31.67. Analysts have raised price targets, with Stifel Nicolaus increasing theirs from $35.00 to $40.00, maintaining a "buy" rating. The stock has a consensus rating of "Moderate Buy" and an average target price of $35.25. The company reported earnings of ($0.45) per share, meeting expectations. Institutional investors have recently increased their stakes in LB Pharmaceuticals, which focuses on developing therapies for neuropsychiatric diseases.</p>

Market Beat

LB Pharmaceuticals

Stifel Financial

Bank of America

STIFEL FINANCIAL CORP 6.125% DEP SHS REP 1/1000 NON CU PF SR C

Stifel Financial Pref Share SFB 5.2 10/15/47

STIFEL FINANCIAL CORP 6.25%NON CUM DEP SHS REP 1/1000TH SER B

STIFEL FINANCIAL CORP 4.50% DEP SHS REP 1/1000TH PREF SHS SR D

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH INT NON CUM PFD QQ

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '5'

BANK OF AMERICA CORPORATION 7.25% NON-CUM PERP CONV PFD SER L

BANK OF AMERICA CORPORATION 5.875%NON CUM DEP SHS REP1/1000TH SER HH

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200TH PRF SERIES '2'

BANK OF AMERICA CORPORATION 5% DEP SHS REPR 1/1000TH NON CUM PFD LL

BANK OF AMERICA CORPORATION DEP SHARES REP 1/1000TH PERP PFD SER 'E'

BANK OF AMERICA CORPORATION INCOME CAPITAL OBLIG NTS DUE 15/12/2066

BANK OF AMERICA CORPORATION 4.375% DP SH RP 1/1000TH IN NON CU PF NN

BANK OF AMERICA CORPORATION DEP SH REP 1/1200TH PRF SER 1 USD25

BANK OF AMERICA CORPORATION 5.375%DEP SHS REP 1/1000TH NON CUM SR KK

BANK OF AMERICA CORPORATION 6%NON CUM DEP SHS EACH REP 1/1000 SER GG

BANK OF AMERICA CORPORATION DEP SHS REP 1/1200 PFD SER 4 USD25

BANK OF AMERICA CORPORATION DEP SHS REP 1/1000TH NON CUM PFD SER SS

BANK OF AMERICA CORPORATION 4.125%DEP SH REP 1/1000 PFD SER PP USD25

Bank of America Corp

LB Pharmaceuticals (NASDAQ:LBRX) Sets New 52-Week High  - Time to Buy?